Skip to content

Study · Non-randomized trial · n = 15 · 2009

5 results

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.

Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR

Bone11 Aug 2009Cited by 121 (Europe PMC)

PMID19679211 (opens in a new tab)DOI10.1016/j.bone.2009.07.091 (opens in a new tab)PepBankPUB-19679211
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In osteopenic postmenopausal women, PINP rose rapidly during teriparatide treatment and continued increasing through treatment completion.

    In plain wordsIn postmenopausal women with low bone density, a bone formation marker rose rapidly during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP response during treatment
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    PINP increase
    8.2%
    first 2 days
    PINP increase
    110.8%
    end of treatment

    Source sentences

    Summary
    During the first 2 days of teriparatide treatment, PINP levels increased rapidly, by 8.2% (90% confidence interval (CI) 6.9%, 9.5%) and continued to increase until the end of treatment to 110.8%.
    1 context sentence
    Summary · context
    We recruited 15 osteopenic postmenopausal women, ages 55-69 (mean 62) years. All received 20 microg teriparatide subcutaneously for 28 days.
  2. 02HumanNon-randomized trialActivity measurement

    In osteopenic postmenopausal women, PICP increased during teriparatide treatment with a less pronounced pattern than PINP.

    In plain wordsIn postmenopausal women with low bone density, PICP increased during teriparatide treatment, less markedly than PINP.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePICP response during treatment
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    PICP increase
    ≥ 75%
    day 28

    Source sentences

    Summary
    PICP and OC showed a similar, but less pronounced, pattern. All three markers increased by at least 75% at day 28.
    1 context sentence
    Summary · context
    We recruited 15 osteopenic postmenopausal women, ages 55-69 (mean 62) years. All received 20 microg teriparatide subcutaneously for 28 days.
  3. 03HumanNon-randomized trialActivity measurement

    In osteopenic postmenopausal women, osteocalcin increased during teriparatide treatment with a less pronounced pattern than PINP.

    In plain wordsIn postmenopausal women with low bone density, osteocalcin increased during teriparatide treatment, less markedly than PINP.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteocalcin response during treatment
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg · subcutaneous · 28 daysAs given in this study (human).

    Measurements

    Osteocalcin increase
    ≥ 75%
    day 28

    Source sentences

    Summary
    PICP and OC showed a similar, but less pronounced, pattern. All three markers increased by at least 75% at day 28.
    1 context sentence
    Summary · context
    We recruited 15 osteopenic postmenopausal women, ages 55-69 (mean 62) years. All received 20 microg teriparatide subcutaneously for 28 days.
  4. 04HumanNon-randomized trialActivity measurement

    In osteopenic postmenopausal women, bone resorption markers showed a small transient decrease during teriparatide treatment.

    In plain wordsIn postmenopausal women with low bone density, bone breakdown markers decreased slightly and temporarily during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBone resorption marker response during treatment
    Study

    n = 15

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg · subcutaneous · 28 daysAs given in this study (human).

    Source sentences

    Summary
    A small, transient decrease in bone resorption markers occurred over the same period.
    1 context sentence
    Summary · context
    We recruited 15 osteopenic postmenopausal women, ages 55-69 (mean 62) years. All received 20 microg teriparatide subcutaneously for 28 days.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialActivity measurement

    In osteopenic postmenopausal women, bone formation markers fell after teriparatide cessation to within 20% of pretreatment baseline by study day 56.

    In plain wordsIn postmenopausal women with low bone density, bone formation markers approached baseline after teriparatide stopped.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBone formation markers after treatment cessation
    Study

    n = 15

    Comparator
    End of treatment
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Distance from pretreatment baseline
    ≤ 20%
    study day 56, 28 days after treatment cessation

    Source sentences

    Summary
    Following cessation of treatment, concentrations of bone formation markers decreased to within 20% of baseline values by day 56.
    1 context sentence
    Summary · context
    We recruited 15 osteopenic postmenopausal women, ages 55-69 (mean 62) years. All received 20 microg teriparatide subcutaneously for 28 days.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.